Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are effective in CKD with proteinuria [31], and some reports support improvement of tolvaptan effects when combined with an SGLT2 inhibitor in ADPKD patients with proteinuria [32,33]. This evidence concerns the gene SLC5A2 and autosomal dominant polycystic kidney disease.